人工智能在免疫肿瘤学中预测性生物标志物发现的应用:一项系统综述
本系统综述纳入90项研究,评估人工智能(AI)在癌症患者免疫检查点抑制剂(ICI)疗效预测中的生物标志物发现应用,涵盖基因组学、影像组学、数字病理学及真实世界和多模态数据。多数研究使用标准机器学习方法,非小细胞肺癌最常见。AI方法拓展了生物标志物发现视野,但无研究提供可立即改变实践的高级别证据,需前瞻性试验设计。
要点
- 共纳入90项研究,80%于2021-2022年发表,非小细胞肺癌占36%。
- 72%研究使用标准机器学习,22%使用深度学习,6%两者均用。
- 无前瞻性研究设计从一开始就整合AI方法,均为事后分析。
核心结论
- 基于AI的方法拓展了生物标志物发现的视野,展示了整合现有数据集多模态数据发现新元生物标志物的能力。
- 多数纳入研究显示AI预测免疫治疗获益有前景,但无一提供可立即改变实践的高级别证据。
- 需要预先计划的前瞻性试验设计,以覆盖这些软件生物标志物从开发、验证到整合入临床实践的全生命周期步骤。
研究设计与样本
- 系统文献综述,纳入同行评议的原创文章,研究癌症患者ICI疗效预测,覆盖基因组学(包括基因组学、转录组学和表观基因组学)、影像组学、数字病理学(病理组学)以及真实世界和多模态数据五种数据模态。
- 共纳入90项研究,其中37项涉及基因组数据,20项影像组学,8项病理组学,20项真实世界数据,5项多模态数据。
- 72%研究使用标准机器学习方法,22%使用深度学习方法,6%两者均用。
- 研究最多的癌症类型为非小细胞肺癌(36%),其次为黑色素瘤(16%),25%为泛癌研究。
- 无前瞻性研究设计从一开始就纳入基于AI的方法;所有研究均将AI作为事后分析实施。
主要发现
- 在影像组学和病理组学中,使用AI方法识别了ICI的新型生物标志物,分子生物标志物已从基因组学扩展到转录组学和表观基因组学。
- 通过整合多模态/多组学数据,复杂算法和新型AI标志物(如元生物标志物)正在涌现。
- 80%的研究发表于2021-2022年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无前瞻性研究设计从一开始就纳入基于AI的方法;所有研究均将AI作为事后分析实施。
- 无一研究提供可立即改变实践的高级别证据。
- 需要预先计划的前瞻性试验设计,以覆盖这些软件生物标志物从开发、验证到整合入临床实践的全生命周期步骤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The widespread use of immune checkpoint inhibitors (ICIs) has revolutionised treatment of multiple cancer types. However, selecting patients who may benefit from ICI remains challenging. Artificial intelligence (AI) approaches allow exploitation of high-dimension oncological data in research and development of precision immuno-oncology. MATERIALS AND METHODS: We conducted a systematic literature review of peer-reviewed original articles studying the ICI efficacy prediction in cancer patients across five data modalities: genomics (including genomics, transcriptomics, and epigenomics), radiomics, digital pathology (pathomics), and real-world and multimodality data. RESULTS: A total of 90 studies were included in this systematic review, with 80% published in 2021-2022. Among them, 37 studies included genomic, 20 radiomic, 8 pathomic, 20 real-world, and 5 multimodal data. Standard machine learning (ML) methods were used in 72% of studies, deep learning (DL) methods in 22%, and both in 6%. The most frequently studied cancer type was non-small-cell lung cancer (36%), followed by melanoma (16%), while 25% included pan-cancer studies. No prospective study design incorporated AI-based methodologies from the outset; rather, all implemented AI as a post hoc analysis. Novel biomarkers for ICI in radiomics and pathomics were identified using AI approaches, and molecular biomarkers have expanded past genomics into transcriptomics and epigenomics. Finally, complex algorithms and new types of AI-based markers, such as meta-biomarkers, are emerging by integrating multimodal/multi-omics data. CONCLUSION: AI-based methods have expanded the horizon for biomarker discovery, demonstrating the power of integrating multimodal data from existing datasets to discover new meta-biomarkers. While most of the included studies showed promise for AI-based prediction of benefit from immunotherapy, none provided high-level evidence for immediate practice change. A priori planned prospective trial designs are needed to cover all lifecycle steps of these software biomarkers, from development and validation to integration into clinical practice.
引用
- Prelaj A, Miskovic V, Zanitti M, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol. 2023. PMID: 37879443. doi:10.1016/j.annonc.2023.10.125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。